Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

3 Reasons Intuitive Surgical, Inc. Stock Could Rise
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE: LLY) was founded in 1876, while Pfizer Inc. (NYSE: PFE) began....
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE: LLY) was founded in 1876, while Pfizer Inc. (NYSE: PFE) began....
3 Stocks That Pay You
3 Stocks That Pay You
Other than the obvious reason that investors like the steady stream of income that comes from investing in dividend-paying stocks, the stability it conveys about a particular business provides a....
3 Stocks That Pay You
3 Stocks That Pay You
Other than the obvious reason that investors like the steady stream of income that comes from investing in dividend-paying stocks, the stability it conveys about a particular business provides a....

	 
ALPHA MOS : Communiqué normé - Cible
ALPHA MOS : Communiqué normé - Cible
COMMUNIQUE RELATIF AU DEPOT D'UN PROJET DE NOTE EN REPONSE A L'OFFRE PUBLIQUE D'ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE Alpha MOS INITIEE CONJOINTEMENT PAR Jolt capital Ambrosia....
5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
One of the best ways to measure how much a stock is hated is by looking at the percentage of the stock's float that's sold short. Short-sellers think so poorly of a stock that they're willing to....
3 Dividend Stocks That Thrive in Bear Markets
3 Dividend Stocks That Thrive in Bear Markets
One of the benefits of dividend investing is the comfort that comes from the regular income stream. But market downturns can many times throw that sense of security out the window. What income....
3 Dividend Stocks That Thrive in Bear Markets
3 Dividend Stocks That Thrive in Bear Markets
One of the benefits of dividend investing is the comfort that comes from the regular income stream. But market downturns can many times throw that sense of security out the window. What income....
Why bluebird bio Inc Continued Its March Higher Again Today
Why bluebird bio Inc Continued Its March Higher Again Today
Shares of bluebird bio (NASDAQ: BLUE) continued their seemingly unstoppable march higher this week, jumping another 10.8% today as of 2:58 p.m. EDT after two analysts increased their price targets....
Why bluebird bio Inc Continued Its March Higher Again Today
Why bluebird bio Inc Continued Its March Higher Again Today
Shares of bluebird bio (NASDAQ: BLUE) continued their seemingly unstoppable march higher this week, jumping another 10.8% today as of 2:58 p.m. EDT after two analysts increased their price targets....
Why bluebird bio Inc Continued Its March Higher Again Today
Why bluebird bio Inc Continued Its March Higher Again Today
Shares of bluebird bio (NASDAQ: BLUE) continued their seemingly unstoppable march higher this week, jumping another 10.8% today as of 2:58 p.m. EDT after two analysts increased their price targets....
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....

	 
BASTIDE : Chiffre d'affaires annuel : 218 M EUR en croissance de près de 14%
BASTIDE : Chiffre d'affaires annuel : 218 M EUR en croissance de près de 14%
En K€ 2015-2016 2016-2017 Croissance Chiffre d'affaires 4ème trimestre 48 901 55 638 +13,8% Chiffre d'affaires annuel 191 850 218 033 + 13,7%   Le....
Found: 3 Stocks Retirees Should Consider Adding
Found: 3 Stocks Retirees Should Consider Adding
In the hunt for stocks to carry you through your retirement, you're probably looking for low-volatility stocks that supply reliable, steadily rising streams of income. You're past the time....
Found: 3 Stocks Retirees Should Consider Adding
Found: 3 Stocks Retirees Should Consider Adding
In the hunt for stocks to carry you through your retirement, you're probably looking for low-volatility stocks that supply reliable, steadily rising streams of income. You're past the time....
Why Investors Bid Immunogen Inc. Up Almost 12% Today
Why Investors Bid Immunogen Inc. Up Almost 12% Today
News that Irish biotech Jazz Pharmaceuticals (NASDAQ: JAZZ) had signed on to collaborate with Immunogen Inc. (NASDAQ: IMGN) in the development of drugs in the smaller, Massachusetts-based....